Opexa said that the newly issued patents are US patent nos 7,695,713 and 7,658,926, the granted claims of which are directed to its proprietary process for manufacturing its T-cell vaccines as well as to compositions of such vaccines having reactivity to critical MS antigens.
Additionally, a notice of allowance has also been received for Opexa’s US Patent Application serial no 10/520,296, which is directed to T-cell vaccines based on autoreactive T-cell receptor epitopes found in most of the MS patients.
Neil Warma, president and CEO of Opexa, said: “Strengthening our patent position in the area of T-cell technology has been a key objective for us over the past twelve months and is important for Opexa’s long term value.
“Our T-cell technology is the backbone of the Tovaxin development program which is in late clinical development for the treatment of MS. We view intellectual property protection as critical for maintaining and enhancing our long term competitive position.”